دانشگاه تربیت دبیر شهید رجائی
انتشارات دانشگاه تربیت دبیر شهید رجائی

  اخبار و اعلانات

 آمار

تعداد نشریات11
تعداد شماره‌ها210
تعداد مقالات2,098
تعداد مشاهده مقاله2,877,161
تعداد دریافت فایل اصل مقاله2,084,970
Mohamadi, A., Habibi, M., Parandin, F.. (1403). Integration of Clinical, Genetic, and Molecular Features in Predicting Castration Resistance Events in Prostate Cancer: A Comprehensive Machine Learning Analysis. فناوری آموزش, 12(2), 363-372. doi: 10.22061/jecei.2024.10406.697
A. Mohamadi; M. Habibi; F. Parandin. "Integration of Clinical, Genetic, and Molecular Features in Predicting Castration Resistance Events in Prostate Cancer: A Comprehensive Machine Learning Analysis". فناوری آموزش, 12, 2, 1403, 363-372. doi: 10.22061/jecei.2024.10406.697
Mohamadi, A., Habibi, M., Parandin, F.. (1403). 'Integration of Clinical, Genetic, and Molecular Features in Predicting Castration Resistance Events in Prostate Cancer: A Comprehensive Machine Learning Analysis', فناوری آموزش, 12(2), pp. 363-372. doi: 10.22061/jecei.2024.10406.697
Mohamadi, A., Habibi, M., Parandin, F.. Integration of Clinical, Genetic, and Molecular Features in Predicting Castration Resistance Events in Prostate Cancer: A Comprehensive Machine Learning Analysis. فناوری آموزش, 1403; 12(2): 363-372. doi: 10.22061/jecei.2024.10406.697

Integration of Clinical, Genetic, and Molecular Features in Predicting Castration Resistance Events in Prostate Cancer: A Comprehensive Machine Learning Analysis

Journal of Electrical and Computer Engineering Innovations (JECEI)
مقاله 6، دوره 12، شماره 2، مهر 2024، صفحه 363-372    اصل مقاله (869.71 K)
نوع مقاله: Original Research Paper
شناسه دیجیتال (DOI): 10.22061/jecei.2024.10406.697
نویسندگان
A. Mohamadi؛ M. Habibi؛ F. Parandin*
Department of Electrical Engineering, Kermanshah Branch, Islamic Azad University, Kermanshah, Iran.
تاریخ دریافت: 03 آذر 1402،  تاریخ بازنگری: 02 اسفند 1402،  تاریخ پذیرش: 16 اسفند 1402 
چکیده
Background and Objectives: Metastatic castration-sensitive prostate cancer (mCSPC) represents a critical juncture in the management of prostate cancer, where the accurate prediction of the onset of castration resistance is paramount for guiding treatment decisions.
Methods: In this study, we underscore the power and efficiency of auto-ML models, specifically the Random Forest Classifier, for their low-code, user-friendly nature, making them a practical choice for complex tasks, to develop a predictive model for the occurrence of castration resistance events (CRE (. Utilizing a comprehensive dataset from MSK (Clin Cancer Res 2020), comprising clinical, genetic, and molecular features, we conducted a comprehensive analysis to discern patterns and correlations indicative of castration resistance. A random forest classifier was employed to harness the dataset's intrinsic interactions and construct a robust predictive model.
Results: We used over 18 algorithms to find the best model, and our results showed a significant achievement, with the developed model demonstrating an impressive accuracy of 75% in predicting castration resistance events. Furthermore, the analysis highlights the importance of specific features such as 'Fraction Genome Altered ‘and the role of prostate specific antigen (PSA) in castration resistance prediction.
Conclusion: Corroborating these findings, recent studies emphasize the correlation between high 'Fraction Genome Altered' and resistance and the predictive power of elevated PSA levels in castration resistance. This highlights the power of machine learning in improving outcome predictions vital for prostate cancer treatment. This study deepens our insights into metastatic castration-sensitive prostate cancer and provides a practical tool for clinicians to shape treatment strategies and potentially enhance patient results.
کلیدواژه‌ها
Metastatic Castration-sensitive Prostate Cancer؛ Castration Resistance؛ Random Forest Classifier؛ Personalized Medicine؛ Machine Learning
مراجع

[1] Y. Kim, M. Alhassan, “Analyzing factors enabling prostate cancer screening behaviors among African American males in the south region using the Andersen's behavioral model of healthcare services utilization,” J. Prev., 44(2): 253-266, 2022.

[2] H. Rahbar, P. Karabon, M. Menon, Q. D. Trinh, F. Abdollah, “trends in prostate-specific antigen screening since the implementation of the 2012 US preventive services task force recommendations,” Eur. Urol. Focus., 4(6): 1002-1004, 2017.

[3] D. C. Parker, M. S. Cookson, “The changing landscape in the management of newly diagnosed castration sensitive metastatic prostate cancer,” Investig. Clin. Urol., 61(1): S3-S7, 2020.

[4] W. K. B. Ranasinghe, N. A. Brooks, M. A. Elsheshtawi, J. W. Davis, T. K. Bathala, C. Tang, et al., “Patterns of metastases of prostatic ductal adenocarcinoma,” Cancer, 126(16): 3667-3673, 2020.

[5] W. Ranasinghe, D. D. Shapiro, M. Zhang, T. Bathala, N. Navone, T. C. Thompson, et al. “Optimizing the diagnosis and management of ductal prostate cancer,” Nat. Rev. Urol., 18(6): 337-358, 2021.

[6] E. Gupta, T. Guthrie, W. Tan, “Changing paradigms in management of metastatic castration-resistant prostate cancer(mCRPC),” BMC Urol., 14(55), 2014.

[7] D. Kristiyanto, K. E. Anderson, L. H. Hung, K. Y. Yeung, “Predicting discontinuation of docetaxel treatment for metastatic castration resistant prostate cancer (mCRPC) with randomforest,” F1000Res., 5: 8353, 2016.

[8] M. S. Cookson, W. T. Lowrance, M. H. Murad, A. S. Kibel, “Castration-Resistant prostate cancer: AUA guideline amendment,” J. Urol., 193(2): 491-499, 2015.

[9] A.Heidenreich, P. J. Bastian, J. Bellmunt, M. Bolla, S. Joniau, et al. “EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer,” Eur. Urol., 65(2): 467-479, 2014.

[10] I.F. Tannock, R. de-Wit, W. R. Berry, J. Horti, A. Pluzanska, et al. “Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer,” N. Engl. J. Med., 351: 1502-1512, 2004.

[11] D. P. Petrylak, “Docetaxel-based chemotherapy trials in androgen-independent prostate cancer: first demonstration of a survival benefit,” Current Oncol. Rep.,  7(3): 205-206, 2005.

[12] D. P. Petrylak, C. M. Tangen, M. H. A. Hussain, P. N. Lara Jr, J. A. Jones, M. E. Taplin, P. A. Burch, D. Berry, C. Moinpour, M. Kohli, et al., “Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer,” N. Engl. J. Med., 351: 1513-1520, 2004.

[13] A. J. Templeton, F. E. Vera-Badillo, L. Wang, M. Attalla, P. De Gouveia, R. Leibowitz-Amit, J. J. Knox, M. Moore, S. S. Sridhar, A. M. Joshua, et al. “Translating clinical trials to clinical practice: Outcomes of men with metastatic castration-resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials,” Ann. Oncol., 24: 2972-2977, 2013.

[14] C. J. Sweeney, Y. H. Chen, M. Carducci, G. Liu, D. F. Jarrard, M. Eisenberger, Y. N. Wong, N. Hahn, M. Kohli, M. M. Cooney, et al., “therapy in metastatic hormone-sensitive prostate cancer,” N. Engl. J. Med., 373: 737-746, 2015.

[15] K. Deng, H. Li, Y. Guan,  “Treatment stratification of patients with metastatic castration-resistant prostate cancer by machine learning,” iScience, 23(2): 100804, 2020.

[16] D. Bansal, M. A. Reimers, E. M. Knoche, R. K. Pachynski,” immunotherapy and immunotherapy combinations in metastatic castration-resistant prostate cancer,” Cancers, 13(2): 334, 2021.

[17] L. H. Xiao, P. R. Chen, Z. P. Gou, Y. Z. Li, M. Li, L. C. Xiang, P. Feng, “Prostate cancer prediction using the random forest algorithm that takes into account transrectal ultrasound findings, age, and serum levels of prostate-specific antigen,” Asian J. Andrology, 19(5):586-590, 2017.

[18] A. R. Hansen, et al., “Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of high dose pantoprazole (Autophagy Inhibitor) with docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC),” The Oncologist, 24(9): 1188-1194, 2019.

[19] S. Saito, S. Sakamoto, K. Higuchi, et al., “Machine-learning predicts time-series prognosis factors in metastatic prostate cancer patients treated with androgen deprivation therapy,” Sci. Rep., 13: 6325, 2023.

[20] K. H. Stopsack, et al. “Oncogenic genomic alterations, clinical phenotypes, and outcomes in metastatic castration-sensitive prostate cancer,” Clin. Cancer Res., 26(13): 3230-3238, 2020.

[21] F. Parandin, A. Mohamadi, "Designing and optimizing a photonic crystal-based all-optical XOR gate using machine learning,” Majlesi J. Electr. Eng.,  18(1): 1-8, 2024.

[22] F. Parandin, M. R. Malmir, “Low delay time all optical NAND, XNOR and OR logic gates based on 2D photonic crystal structure,” J. Electr. Comput. Eng. Innovations, 8(1): 1-8, 2020.

[23] M. Feli, F. Parandin, “A numerical optimization of an efficient double junction InGaN/CIGS solar cell,” J. Electr. Comput. Eng. Innovations, 6(1): 53-58, 2018.

[24] V. Y. Kulkarni, P.K. Sinha, "Random forest classifiers: a survey and future research directions," Int. J. Adv. Comput., 36(1): 1144-1153, 2013.

[25] A. Parmar, R. Katariya, V. Patel, "A review on random forest: An ensemble classifier," in Proc. International Conference on Intelligent Data Communication Technologies and Internet of Things (ICICI) 2018:  758-763, 2018.

[26] A. B. Shaik, S. Srinivasan, "A brief survey on random forest ensembles in classification model," in Proc. International Conference on Innovative Computing and Communications (ICICC),  2: 253-260, 2018.

[27] P. Probst, M. N. Wright, A. Boulesteix, "Hyperparameters and tuning strategies for random forest," WIREs: Data Min. Knowl. Discovery, 9(3): e1301, 2019.

[28] J. Hancock, T. M. Khoshgoftaar, "Impact of hyperparameter tuning in classifying highly imbalanced big data," in Proc. 2021 IEEE 22nd International Conference on Information Reuse and Integration for Data Science (IRI): 348-354, 2021.

[29] H. L. Le, D. H. Tran, D. V. Chau, "A survey on the impact of hyperparameters on random forest performance using multiple accelerometer datasets," Int. J. Comput. Appl., 30(4): 351-361, 2023.

[30] K. E. Hoque, H. Aljamaan, "Impact of hyperparameter tuning on machine learning models in stock price forecasting," IEEE Access, 9: 163815-163830, 2021.

[31] H. J. P. Weerts, A. C. Mueller, J. Vanschoren, "Importance of tuning hyperparameters of machine learning algorithms," arXiv preprint arXiv:2007.07588, 2020.

[32] R. K. Singla, C. S. Sai, H. Chopra, S. Behzad, H. Bansal, R. Goyal, R. K. Gautam, C. Tsagkaris, S. Joon, S. Singla, B. Shen, “Natural products for the management of castration-resistant prostate cancer: Special focus on nanoparticles based studies,” Front Cell Dev. Biol., 9: 745177, 2021.

[33] S. Nakanishi, M. Goya, et al., “Three-month early change in prostate-specific antigen levels as a predictive marker for overall survival during hormonal therapy for metastatic hormone-sensitive prostate cancer,” BMC Res. Notes, 14: 227, 2021.

آمار
تعداد مشاهده مقاله: 390
تعداد دریافت فایل اصل مقاله: 126


سامانه مدیریت نشریات علمی. طراحی و پیاده سازی از سیناوب